Factors predicting Public Disclosure of Results (PDOR) of completed studies (publication and/or posting to ClinicalTrials.gov (CTG) website).

<p>Factors predicting Public Disclosure of Results (PDOR) of completed studies (publication and/or posting to ClinicalTrials.gov (CTG) website).</p

Effect of funding and study phase on proportion of studies that made available their primary outcomes in ClinicalTrials.gov website by time since study completion.

<p>This X axis indicates days from study completion and Y axis indicates proportion of studies that posted results to CTG. - Green line shows phase 2 and industry studies. - Blue line shows phase 2 and non-industry/blended studies. - Red line shows phase 3/4 and industry studies. - Brown line shows phase 3/4 and non-industry/blended studies. * Proportions of result posting to CTG by each group is shown in Table S6 in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0101826#pone.0101826.s001" target="_blank">Appendix S1</a>.</p

Flow diagram of the data selection.

<p>This explains how the clinical trials for the analyses were selected.</p

Cumulative rates of Public Disclosure of Results (PDOR) among selected studies categorized by funding source and phase of development (days from study completion to publication and/or posting to ClinicalTrials.gov website).

<p>This X axis indicates days from study completion and Y axis indicates proportion of studies that achieved PDOR. - Green line shows phase 2 and industry studies. - Blue line shows phase 2 and non-industry/blended studies. - Red line shows phase 3/4 and industry studies. - Brown line shows phase 3/4 and non-industry/blended studies. * The median times to PDOR by each group is shown in Table S4 in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0101826#pone.0101826.s001" target="_blank">Appendix S1</a>.</p

Numbers of completed studies achieving Public Disclosure of Results (PDOR), publication and result posting to ClinicalTrials.gov (CTG) website, and time to do so (N = 400).

<p>*Results limited to those studies that ever achieved PDOR (publication and/or posting to CTG).</p

Characteristics of the Studies Selected (N = 400).

<p>*Phase 3 and 4 were aggregated as “phase 3/4”, non-industry funded and blended studies were aggregated as “non-industry or blended” and female only and male only were aggregated as “male or female only” in the analysis.</p><p>**Some data were missing in CTG registry and the total number did not sum up 400.</p

Consistent Aggregation of Linear Complementarity Problems

Aggregating linear complementarity problems under a general definition of constrained consistency leads to the possibility of consistent aggregation of linear and quadratic programming models. Under this formulation, consistent aggregation of dual variables is also achieved. Furthermore, the existence of multiple sets of aggregation operators is illustrated with a numerical example. Such multiple operators allow considerable flexibility of the microstructures admitting consistent aggregation

Additional file 1 of The parthenocarpic gene Pat-k is generated by a natural mutation of SlAGL6 affecting fruit development in tomato (Solanum lycopersicum L.)

Table S1. Raw data status of whole genome re-sequencing of ‘MPK-1’. Table S2. Primer sequences used for fine mapping. Table S3. Primer sequences used for primer walking of the insertion in the Solyc01g093960 gene. Table S4. Primer sequences used for quantitative RT-PCR analysis of the Solyc01g093960 gene. Table S5. The information of SNPs used in QTL analysis in this study. Table S6. The information of SNPs for fine mapping of Pat-k in this study. Figure S1. Amplification products produced by the primers of 093960_fwd and 093960_rev. (XLSX 136 kb

Genetic interaction of the <i>Se14</i> locus with other flowering time genes loci.

<p>Comparison of flowering time among single mutant lines for flowering time: A) <i>hd1</i>, B) <i>ghd7</i>, C) ehd1 and D) <i>se13</i>, and their double mutant lines for <i>se14</i>. These lines were grown under ND.</p

Map-based cloning of <i>Se14</i> and structural comparison of the proteins between Se14 and ELF6.

<p>A) Chromosomal location of <i>Se14</i> and marker positions on chromosome 3. B) High-resolution linkage map of <i>Se14</i> and genes annotated in the Rice Annotation Project Database (RAP-DB; <a href="http://rapdb.lab.nig.ac.jp" target="_blank">http://rapdb.lab.nig.ac.jp</a>). C) Genomic structure of the candidate region and the mutation in HS112. D) Schematic domain structure of two loci, Os03g0151300 and Os03g0151400, annotated at RAP-DB, and their combined cDNA.</p